Data Presented at Two Global Medical Congresses Reinforce Benefit of EnbrelŪ (etanercept) for Patients with Chronic Inflammatory Conditions

Wednesday, May 25, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis

CONTACT:

Amgen

Pfizer

Christine Regan (media)

Victoria Davis (media)

Office: 805-447-5476

Office: 212-733-3227

Cell: 617-359-1324

Cell: 347-558-3455

Arvind Sood (investors)

Jennifer M. Davis (investors)

Office: 805-447-1060

Office: 212-733-0717

Carrie Deverell, +41 41 3690 308 (European media)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store